| Benz Mining Corp (BNZ) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$567 |
Change in substantial holding from SPR
|
28 Jul 2025 10:32AM |
$0.590 |
$1.985 |
risen by
236.44%
|
|
| Australian Rare Earths Limited (AR3) ORDINARY FULLY PAID |
Materials |
$36 |
Application for quotation of securities - AR3
|
28 Jul 2025 10:29AM |
$0.130 |
$0.140 |
risen by
7.69%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$86 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Jul 2025 10:29AM |
$0.105 |
$0.071 |
fallen by
32.38%
|
|
ALA - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers the period ending 31 March 2024.
- Arovella continued development of its ALA-101 and ALA-104 cell therapy programs targeting blood cancers.
- Progress made in manufacturing and preclinical development of ALA-101, including collaboration with clinical and manufacturing partners.
- ALA-104 program advanced with further research and development activities.
- New collaborations and licensing agreements established to expand the company's pipeline and capabilities.
- Ongoing regulatory and quality assurance activities to support progression toward clinical trials.
- Report includes Appendix 4C Cash Flow statement, outlining receipts from customers, research and development outflows, and overall financial position.
- Company maintains focus on capital management to fund its research and operational activities.
- No significant changes in business activities or control over entities during the quarter.
- The company is actively seeking additional funding sources to support continued operations and growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bowen Coking Coal Limited (BCB) ORDINARY FULLY PAID |
Materials |
$8 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Jul 2025 10:28AM |
$0.075 |
$0.075 |
fallen by
0%
|
|
| NuEnergy Gas Limited (NGY) ORDINARY FULLY PAID |
Energy |
$90 |
Commenced spudding of third well - TE-B-6--3
|
28 Jul 2025 10:26AM |
$0.035 |
$0.047 |
risen by
34.29%
|
|
| Bowen Coking Coal Limited (BCB) ORDINARY FULLY PAID |
Materials |
$8 |
Continuation of Suspension from Quotation
|
28 Jul 2025 10:23AM |
$0.075 |
$0.075 |
fallen by
0%
|
|
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$98 |
CEO Appointment Joe Coote
|
28 Jul 2025 10:22AM |
$0.180 |
$0.110 |
fallen by
38.89%
|
|
BUB - Price-sensitive ASX Announcement
Full Release
Key Points
- Joe Coote appointed as CEO of Bubs Australia Limited
- Coote has significant experience in the dairy and infant nutrition sectors
- The board emphasizes confidence in Coote’s ability to drive growth
- Strategic priorities include expansion and profitability improvement
- Joe Coote’s previous roles include leadership positions at major industry companies
- Appointment aligns with Bubs’ commitment to strengthen its market position
- The board welcomes Joe Coote and anticipates positive impact on company direction
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brightstar Resources Limited (BTR) ORDINARY FULLY PAID |
Materials |
$373 |
Security Holder Support Received for BTR
|
28 Jul 2025 10:18AM |
$0.480 |
$0.340 |
fallen by
29.17%
|
|
| Aurumin Limited (AUN) ORDINARY FULLY PAID |
Materials |
- |
Security Holder Support Received for BTR
|
28 Jul 2025 10:18AM |
$0.110 |
$0.105 |
fallen by
4.55%
|
|
| MA Credit Income Trust (MA1) ORDINARY UNITS FULLY PAID |
- |
$549 |
Dividend/Distribution - MA1
|
28 Jul 2025 10:17AM |
$2.040 |
$1.965 |
fallen by
3.68%
|
|
| Gold Mountain Limited (GMN) ORDINARY FULLY PAID |
Materials |
$22 |
Change of Director's Interest Notice on Consolidation x 3
|
28 Jul 2025 10:16AM |
$0.100 |
$0.110 |
risen by
10%
|
|
| Moab Minerals Limited (MOM) ORDINARY FULLY PAID |
Materials |
$4 |
Quarterly Activities Report and Appendix 5B
|
28 Jul 2025 10:11AM |
$0.001 |
$0.002 |
risen by
100%
|
|
MOM - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities Report and Appendix 5B released for period ending 31 December 2023.
- Ongoing exploration and target generation at the Woodlands Project, Western Australia.
- Further geological mapping and soil sampling conducted.
- Assessment of lithium and critical minerals prospects continued.
- Appointment of new Managing Director announced.
- Appendix 5B summarises company’s cash flows, focusing on exploration and evaluation outflows.
- Company maintains stable financial position with adequate cash reserves.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ventus Medical, Inc. (VNT2) ORDINARY FULLY PAID |
- |
- |
Webcast and Conference Call details for HY25 Results
|
28 Jul 2025 10:10AM |
n/a |
n/a |
n/a
|
|
| International Graphite Limited (IG6) ORDINARY FULLY PAID |
Industrials |
$9 |
Reinstatement to Quotation
|
28 Jul 2025 10:10AM |
$0.072 |
$0.047 |
fallen by
34.72%
|
|
IG6 - Price-sensitive ASX Announcement
Full Release
Key Points
- International Graphite Limited (IG6) has been reinstated to quotation on the ASX.
- The company operates graphite mining and processing projects in Western Australia.
- Reinstatement follows compliance with ASX listing rules and completion of capital raising.
- Funds raised will be used for project development, working capital, and exploration.
- Updates are provided on the Springdale Graphite Project and Collie downstream processing facility.
- The company remains committed to progressing its graphite business strategy.
- Board and management changes are detailed as part of ongoing corporate development.
- Recent financial activities and share structure updates are disclosed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| International Graphite Limited (IG6) ORDINARY FULLY PAID |
Industrials |
$9 |
Agreement to develop new Expandable Graphite facility
|
28 Jul 2025 10:09AM |
$0.072 |
$0.047 |
fallen by
34.72%
|
|
IG6 - Price-sensitive ASX Announcement
Full Release
Key Points
- International Graphite Limited (IG6) and a Chinese industrial group have entered a non-binding agreement.
- The agreement is to develop and construct a new expandable graphite facility in Collie, Western Australia.
- Graphite feedstock will be sourced from IG6’s Springdale Graphite Project and processed at the Collie facility.
- The Chinese partner will contribute technology, design, and market access.
- The agreement supports IG6’s strategy to establish an integrated Australian graphite supply chain.
- Expandable graphite is a value-added product used in batteries and flame retardant applications.
- The partnership accelerates IG6’s timeline for entering the expandable graphite market.
- The facility aims to serve both domestic and international markets.
- The agreement remains subject to due diligence, definitive documentation, and regulatory approvals.
- Project supports Western Australia’s ambitions in critical minerals processing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| International Graphite Limited (IG6) ORDINARY FULLY PAID |
Industrials |
$9 |
Comet share sale and debt repayment
|
28 Jul 2025 10:09AM |
$0.072 |
$0.047 |
fallen by
34.72%
|
|
IG6 - Price-sensitive ASX Announcement
Full Release
Key Points
- International Graphite Limited (IG6) sold 38,000,000 Comet Resources Limited shares.
- The gross proceeds from the sale total $570,000.
- Funds from the sale will be used to fully repay an outstanding loan.
- The debt repayment releases IG6 from previous debt obligations.
- IG6 retains a residual holding in Comet Resources Limited.
- The transaction improves IG6's balance sheet and financial flexibility.
- The company can now focus more on its core operations following the debt repayment.
- Details of the transaction background and rationale are provided.
- The announcement was made on June 13, 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| wrkr Ltd (WRK) ORDINARY FULLY PAID |
Information Technology |
$208 |
Quarterly Update Presentation
|
28 Jul 2025 10:09AM |
$0.105 |
$0.105 |
fallen by
0%
|
|
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$363 |
Appendix 3Z - J. Todd
|
28 Jul 2025 10:02AM |
$3.710 |
$0.605 |
fallen by
83.69%
|
|
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$363 |
Appendix 3Z - B. Soller
|
28 Jul 2025 10:01AM |
$3.710 |
$0.605 |
fallen by
83.69%
|
|
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$363 |
Appendix 3Z - M. Bernhard
|
28 Jul 2025 10:01AM |
$3.710 |
$0.605 |
fallen by
83.69%
|
|
| Peninsula Energy Limited (PEN) ORDINARY FULLY PAID |
Energy |
$274 |
Sales Contracts and Company Update
|
28 Jul 2025 10:00AM |
$0.620 |
$0.640 |
risen by
3.23%
|
|
PEN - Price-sensitive ASX Announcement
Full Release
Key Points
- Sales contracts reset completed with mutual termination of five contracts.
- Compensation of US$6.6 million agreed for terminated contracts.
- One sales contract remains for delivery of 600,000 lbs from 2028 to 2033.
- Central Processing Plant construction is complete with ongoing commissioning.
- Dry yellowcake production expected in the September quarter.
- Keith Bowes appointed as Non-Executive Director.
- Mark Wheatley and Harrison Barker to retire from Board.
- Efforts underway to secure financing and lift trading suspension.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Peninsula Energy Limited (PEN) ORDINARY FULLY PAID |
Energy |
$274 |
Sales Contracts and Company Update
|
28 Jul 2025 10:00AM |
$0.620 |
$0.640 |
risen by
3.23%
|
|
PEN - Price-sensitive ASX Announcement
Full Release
Key Points
- Termination of five out of six offtake contracts for US$6.6 million.
- Secured a debt facility of up to US$15 million.
- Central Processing Plant nearing completion with water commissioning underway.
- Dried yellowcake production targeted for the September quarter.
- One remaining contract for delivery of 100,000 pounds per annum from 2028 to 2033.
- Keith Bowes appointed as Non-Executive Director.
- Company's focus on securing financing for the reset plan.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BKI Investment Company Limited (BKI) ORDINARY FULLY PAID |
Financials |
$1,384 |
BKI 25 July 2025 Weekly NTA
|
28 Jul 2025 10:00AM |
$1.820 |
$1.715 |
fallen by
5.77%
|
|
| Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID |
Health Care |
$76 |
Positive ATH434 Results from Open-Label Phase 2 Trial in MSA
|
28 Jul 2025 9:59AM |
$0.016 |
$0.007 |
fallen by
56.25%
|
|
ATH - Price-sensitive ASX Announcement
Full Release
Key Points
- ATH434 demonstrated a favorable safety and tolerability profile in MSA patients at both 30mg and 60mg doses.
- Effective drug exposure increased predictably with the higher dose.
- A slower rate of clinical decline was observed in ATH434-treated patients versus a matched Natural History Study cohort, as measured by UMSARS.
- Stabilization of orthostatic hypotension and improvements in other MSA symptoms were reported.
- Results support continued development and a randomized, placebo-controlled Phase 2 clinical trial of ATH434 in MSA.
- ATH434 is a first-in-class small molecule designed to inhibit the accumulation and toxicity of pathological proteins implicated in neurodegenerative diseases.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PainChek Ltd (PCK) ORDINARY FULLY PAID |
Health Care |
$31 |
Proposed issue of securities - PCK
|
28 Jul 2025 9:58AM |
$0.040 |
$0.150 |
risen by
275%
|
|